More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$15.39B
EPS
3.07
P/E ratio
14.8
Price to sales
3.08
Dividend yield
--
Beta
0.386646
Previous close
$241.55
Today's open
$243.30
Day's range
$238.94 - $244.61
52 week range
$156.95 - $266.38
show more
CEO
Renee Gala
Employees
2890
Headquarters
Dublin 4,
Exchange
Nasdaq Global Select
Shares outstanding
64189052
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 7 hours ago

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Zacks Investment Research • Nov 9, 2026

JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
Zacks Investment Research • Nov 3, 2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m.
PRNewsWire • Nov 3, 2026

4 Biotech Stocks Seeing Unusual Options Volume Today
Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
Schaeffers Research • Nov 3, 2026

Jazz Pharmaceuticals Q3 Earnings Call Highlights
Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline.
MarketBeat • Nov 3, 2026

Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® revenues grew 12% YoY with 425 net patient adds in 3Q26 – – Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy portfolio – DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26). "Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.
PRNewsWire • Nov 2, 2026

Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $3.88 per share versus the Zacks Consensus Estimate of a loss of $4.09. This compares to earnings of $8.13 per share a year ago.
Zacks Investment Research • Nov 2, 2026

Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Jazz Pharmaceuticals plc commission-free¹. Build wealth for the long term using automated trading and transfers.